Federated Hermes Inc. Sells 25,879 Shares of McKesson Corporation $MCK

Federated Hermes Inc. cut its position in shares of McKesson Corporation (NYSE:MCK) by 47.8% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 28,214 shares of the company’s stock after selling 25,879 shares during the period. Federated Hermes Inc.’s holdings in McKesson were worth $20,675,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Cary Street Partners Investment Advisory LLC boosted its position in shares of McKesson by 22.7% during the 2nd quarter. Cary Street Partners Investment Advisory LLC now owns 367 shares of the company’s stock valued at $269,000 after acquiring an additional 68 shares during the last quarter. Quantum Portfolio Management LLC raised its stake in McKesson by 26.3% during the second quarter. Quantum Portfolio Management LLC now owns 2,153 shares of the company’s stock valued at $1,578,000 after purchasing an additional 448 shares in the last quarter. Avestar Capital LLC lifted its position in McKesson by 11.9% during the second quarter. Avestar Capital LLC now owns 1,849 shares of the company’s stock valued at $1,356,000 after purchasing an additional 196 shares during the last quarter. StoneX Group Inc. lifted its position in McKesson by 23.6% during the second quarter. StoneX Group Inc. now owns 1,115 shares of the company’s stock valued at $817,000 after purchasing an additional 213 shares during the last quarter. Finally, SageView Advisory Group LLC grew its stake in shares of McKesson by 1.5% in the 2nd quarter. SageView Advisory Group LLC now owns 1,507 shares of the company’s stock worth $1,064,000 after buying an additional 22 shares in the last quarter. Institutional investors own 85.07% of the company’s stock.

McKesson Price Performance

Shares of NYSE MCK opened at $795.27 on Wednesday. McKesson Corporation has a 1 year low of $558.13 and a 1 year high of $895.58. The firm has a 50-day simple moving average of $816.60 and a two-hundred day simple moving average of $746.49. The company has a market cap of $98.16 billion, a P/E ratio of 24.75, a PEG ratio of 1.31 and a beta of 0.38.

McKesson (NYSE:MCK) last issued its quarterly earnings results on Wednesday, November 5th. The company reported $9.86 earnings per share for the quarter, topping the consensus estimate of $8.84 by $1.02. The firm had revenue of $103.15 billion for the quarter, compared to the consensus estimate of $103.80 billion. McKesson had a negative return on equity of 248.14% and a net margin of 1.04%.The company’s revenue for the quarter was up 10.2% on a year-over-year basis. During the same period in the prior year, the business posted $7.07 earnings per share. As a group, equities research analysts expect that McKesson Corporation will post 32.77 EPS for the current year.

McKesson Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, January 2nd. Stockholders of record on Monday, December 1st will be issued a $0.82 dividend. The ex-dividend date is Monday, December 1st. This represents a $3.28 dividend on an annualized basis and a dividend yield of 0.4%. McKesson’s dividend payout ratio is presently 10.21%.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on MCK. UBS Group upped their target price on shares of McKesson from $920.00 to $980.00 and gave the company a “buy” rating in a research report on Thursday, November 6th. Zacks Research cut McKesson from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, November 25th. TD Cowen upped their price objective on McKesson from $830.00 to $864.00 and gave the company a “buy” rating in a research report on Wednesday, September 24th. Robert W. Baird lifted their target price on McKesson from $873.00 to $927.00 and gave the stock an “outperform” rating in a report on Thursday, November 6th. Finally, Barclays started coverage on McKesson in a research report on Monday. They set an “overweight” rating and a $960.00 target price on the stock. One analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $892.86.

Insider Buying and Selling

In related news, CAO Napoleon B. Rutledge, Jr. sold 329 shares of the firm’s stock in a transaction dated Friday, November 7th. The shares were sold at an average price of $861.63, for a total value of $283,476.27. Following the transaction, the chief accounting officer owned 328 shares of the company’s stock, valued at $282,614.64. This trade represents a 50.08% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. 0.08% of the stock is owned by corporate insiders.

McKesson Company Profile

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.